- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03141554
The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome
Study Overview
Status
Conditions
Detailed Description
Disinfectants and oral antiseptics including PVP-I are known to kill microorganisms to a variable extent, at a variable range of time points. Microorganisms may be protected from disinfectants by production of thick masses of cells and extracellular materials, or biofilms. Moreover, antiseptics should not lead to dysbiosis after use. Dysbiosis is a negative change in the microbiome of a particular skin or mucosal region. The Human Microbiome project showed, that every area has a specific microbiota in which the human host lives with an abundance of commensal, synergistic, and potentially pathogenic microorganisms. Antiseptics with efficacy gaps and resistance may induce such dysbiosis, especially after prolonged use.
It is envisaged that twelve healthy volunteers will complete the study. Each healthy volunteer will rinse with the test product according to a developed protocol, between established wash out periods.
The ability of the test product (1% Betadine® PVP-I based mouth wash and gargle) compared to the reference products (0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (No alcohol) and Normal saline gargle) to reduce resident and transient microflora will be assessed. The mouth wash products will also be assessed for their ability to maintain and/or restore balanced microflora.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 119074
- National University of Singapore Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects 21 years and older,
- Not pregnant nor trying to conceive during the study period,
- Non-smoker, non-tobacco user (no chewing of tobacco or similar products),
- No systemic or topical oral antibiotic or antifungal in the past 2 months (from date of consent),
- No ongoing medication (e.g., immunosuppressive medication, no systemic or inhaled glucocorticoids),
- Prepared to use a toothpaste that does not any antimicrobials (Colgate Maximum Cavity Protection) for 2 days after providing consent and during the study,
- Prepared to refrain from using mouth washes/gargles or any other oral hygiene product for 2 days after providing consent and during the study,
- Good oral health (e.g., no visible bleeding, inflammation, oral ulcer or oral lesion, no need for dental treatment),
- Must have given written informed consent.
Exclusion Criteria:
- Allergy or contraindication to any test product substance (active or excipients),
- Known hyperthyroidism,
- Consumption of alcoholic beverages 24 hours before test product administration on Day 0, Day 2, and Day 4,
- Wearing dental appliances (all types of braces, removable or fixed dentures, etc.),
- Minor ailments like cough, cold, upper respiratory tract infection(s), or oral ulcer(s),
- Unwillingness or inability to comply with the requirements of the protocol,
- Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half-lives, whichever is longer) prior to the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment Sequence Group 1
Treatment Sequence Group 1 = A -> B -> C Treatment A = 1% Betadine® PVP-I based mouth wash and gargle Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol) Treatment C = Normal saline gargle (lukewarm). |
1% Betadine® PVP-I based mouth wash and gargle
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Normal saline gargle
|
Active Comparator: Treatment Sequence Group 2
Treatment Sequence Group 2 = B -> C -> A Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol) Treatment C = Normal saline gargle (lukewarm). Treatment A = 1% Betadine® PVP-I based mouth wash and gargle |
1% Betadine® PVP-I based mouth wash and gargle
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Normal saline gargle
|
Active Comparator: Treatment Sequence Group 3
Treatment Sequence Group 3 = C -> A -> B Treatment C = Normal saline gargle (lukewarm). Treatment A = 1% Betadine® PVP-I based mouth wash and gargle Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol) |
1% Betadine® PVP-I based mouth wash and gargle
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Normal saline gargle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composition of oral microbiome - reduction of microflora
Time Frame: Swab 1 - 0 Min, Swab 2 - 3 min (post treatment) and Swab 3 - 240 min (post treatment)
|
The change (amount and variety) of oral microflora species composition from baseline after the usage of a single dose of different antiseptic mouth washes using next generation sequencing (NGS) and real-time PCR techniques at 3 mins and 240 mins .
|
Swab 1 - 0 Min, Swab 2 - 3 min (post treatment) and Swab 3 - 240 min (post treatment)
|
Composition of oral microbiome - maintenance of healthy microflora
Time Frame: Swab 1 - 0 Min, Swab 2 - 3 min (post treatment) and Swab 3 - 240 min (post treatment)
|
The change (amount and variety) of healthy oral microflora species composition from baseline after the usage of a single dose of different antiseptic mouth washes using next generation sequencing (NGS) and real-time PCR techniques at 3 mins and 240 mins.
|
Swab 1 - 0 Min, Swab 2 - 3 min (post treatment) and Swab 3 - 240 min (post treatment)
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTD16-SG-401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Health
-
Fernanda Muñoz SepúlvedaSubvención Presidencial, Ministerio de Hacienda, Chile; Centro Interuniversitario... and other collaboratorsCompletedOral Health Knowledge | Oral Health Attitudes | Oral Health Self-efficacyChile
-
Academia Cearense de OdontologiaCompletedOral Health | Public Health | Diagnosis, OralBrazil
-
Designs for HealthRecruitingA Pilot Study of a Commercially-available Oil Rinse Product (PerioPull™) on Markers of Dental HealthOral HealthUnited States
-
HALEONNot yet recruiting
-
Oral Health Center of Expertise Rogaland, NorwayUniversity of Bergen; University of Agder; University of Stavanger; Regional Research...Recruiting
-
I.M. Sechenov First Moscow State Medical UniversityCompleted
-
GlaxoSmithKlineCompleted
-
The University of Hong KongFood and Health Bureau, Hong KongRecruiting
-
University Hospital, ToulouseUniversity Paul Sabatier of ToulouseTerminated
Clinical Trials on 1% Betadine® PVP-I based mouth wash and gargle,
-
National Taiwan University HospitalCompletedCovid19 | SARS-CoV 2 InfectionTaiwan
-
King Abdulaziz UniversityCompletedCOVID-19 | Covid19 | SARS-CoV-2 | Coronavirus | Saliva | Viral Load | Polymerase Chain Reaction | MouthwashesSaudi Arabia
-
Nina BhardwajCancer Research Institute, New York City; Ludwig Institute for Cancer Research and other collaboratorsCompleted